Roche’s Genentech To Present Pivotal Lung And Breast Cancer Data At ESMO 2026, Highlighting Divarasib Superiority Over Standard Of Care And Giredestrant Efficacy Gains Without Tolerability Or Quality-Of-Life Compromise

Roche's Genentech is set to present pivotal data at ESMO 2026, highlighting the Phase III Krascendo 1 results that show divarasib's superiority over first-generation KRAS G12C inhibitors for advanced G12C-mutated non-small cell lung cancer. Additionally, the Phase III lidERA study indicates that giredestrant offers improved efficacy in early-stage breast cancer without compromising tolerability or quality of life. Further results from a second Phase III trial in China suggest that Tam-Peli, a next-generation B7-H3 targeted ADC, may provide robust efficacy with a favorable safety profile in metastatic nasopharyngeal carcinoma.